Dr Hamish Campbell

Map

Selected grants

2014

  • Delta133p53 in tumour development; Campbell H; DVC Research/Bridging Support Grant.

2012

  • Mechanism of 133p53 isoform oncogenicity; Campbell H; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Mehta, S., Tsai, P., Lasham, A., Campbell, H., Reddel, R., Braithwaite, A., Print, C. (2016). A study of TP53 RNA splicing illustrates pitfalls of RNA-seq methodology. Advances in Cancer Research, 76(24), 7151-7159. [More Information]
  • Slatter, T., Wilson, M., Tang, C., Campbell, H., Ward, V., Young, V., Van Ly, D., Fleming, N., Braithwaite, A., Baird, M. (2016). Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. OncoImmunology, 5(3), 1-14. [More Information]
  • Roth, I., Campbell, H., Rubio, C., Vennin, C., Wilson, M., Wiles, A., Williams, G., Woolley, A., Timpson, P., Berridge, M., Braithwaite, A., et al (2016). The (delta)133p53 isoform and its mouse analogue (delta)122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2. Oncogene, 35(38), 4981-4989. [More Information]
  • Slatter, T., Hung, N., Bowie, S., Campbell, H., Rubio, C., Speidel, D., Wilson, M., Baird, M., Royds, J., Braithwaite, A. (2015). Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell Death and Disease, 6, 1-9. [More Information]
  • Campbell, H., Mehta, R., Neumann, A., Rubio, C., Baird, M., Slatter, T., Braithwaite, A. (2013). Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene, 32(7), 827-836. [More Information]
  • Campbell, H., Slatter, T., Jeffs, A., Mehta, R., Rubio, C., Baird, M., Braithwaite, A. (2012). Does (Delta)133p53 isoform trigger inflammation and autoimmunity? Cell Cycle, 11(3), 446-450. [More Information]
  • Huschtscha-Holliday, L., Napier, C., Noble, J., Bower, K., Au, A., Campbell, H., Braithwaite, A., Reddel, R. (2012). Enhanced isolation of fibroblasts from human skin explants. BioTechniques, 53(4), 239-244. [More Information]
  • Slatter, T., Hung, N., Campbell, H., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A., Braithwaite, A., et al (2011). Hyperproliferation, cancer, and inflammation in mice expressing a delta133p53-like isoform. Blood, 117(19), 5166-5177. [More Information]
  • Huschtscha-Holliday, L., Moore, J., Noble, J., Campbell, H., Royds, J., Braithwaite, A., Reddel, R. (2009). Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1. Journal of Cell Science, 122(16), 2989-2995. [More Information]
  • Chen, Y., Campbell, H., Wiles, A., Eccles, M., Reddel, R., Braithwaite, A., Royds, J. (2008). PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Research, 68(14), 5724-5732. [More Information]

2016

  • Mehta, S., Tsai, P., Lasham, A., Campbell, H., Reddel, R., Braithwaite, A., Print, C. (2016). A study of TP53 RNA splicing illustrates pitfalls of RNA-seq methodology. Advances in Cancer Research, 76(24), 7151-7159. [More Information]
  • Slatter, T., Wilson, M., Tang, C., Campbell, H., Ward, V., Young, V., Van Ly, D., Fleming, N., Braithwaite, A., Baird, M. (2016). Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. OncoImmunology, 5(3), 1-14. [More Information]
  • Roth, I., Campbell, H., Rubio, C., Vennin, C., Wilson, M., Wiles, A., Williams, G., Woolley, A., Timpson, P., Berridge, M., Braithwaite, A., et al (2016). The (delta)133p53 isoform and its mouse analogue (delta)122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2. Oncogene, 35(38), 4981-4989. [More Information]

2015

  • Slatter, T., Hung, N., Bowie, S., Campbell, H., Rubio, C., Speidel, D., Wilson, M., Baird, M., Royds, J., Braithwaite, A. (2015). Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell Death and Disease, 6, 1-9. [More Information]

2013

  • Campbell, H., Mehta, R., Neumann, A., Rubio, C., Baird, M., Slatter, T., Braithwaite, A. (2013). Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene, 32(7), 827-836. [More Information]

2012

  • Campbell, H., Slatter, T., Jeffs, A., Mehta, R., Rubio, C., Baird, M., Braithwaite, A. (2012). Does (Delta)133p53 isoform trigger inflammation and autoimmunity? Cell Cycle, 11(3), 446-450. [More Information]
  • Huschtscha-Holliday, L., Napier, C., Noble, J., Bower, K., Au, A., Campbell, H., Braithwaite, A., Reddel, R. (2012). Enhanced isolation of fibroblasts from human skin explants. BioTechniques, 53(4), 239-244. [More Information]

2011

  • Slatter, T., Hung, N., Campbell, H., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A., Braithwaite, A., et al (2011). Hyperproliferation, cancer, and inflammation in mice expressing a delta133p53-like isoform. Blood, 117(19), 5166-5177. [More Information]

2009

  • Huschtscha-Holliday, L., Moore, J., Noble, J., Campbell, H., Royds, J., Braithwaite, A., Reddel, R. (2009). Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1. Journal of Cell Science, 122(16), 2989-2995. [More Information]

2008

  • Chen, Y., Campbell, H., Wiles, A., Eccles, M., Reddel, R., Braithwaite, A., Royds, J. (2008). PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Research, 68(14), 5724-5732. [More Information]

To update your profile click here. For support on your academic profile contact .